New Nukes, Old Nukes

Nuclear Waste How to get overwhelmed by the data on new nukes, old nukes & lots of different classes of ART at AIDS 2014 by Mariel...

Barriers to Treatment Use

LifeGuide Opening Doors A new survey uncovers barriers to treatment by Chael Needle There’s an old chestnut that goes something like this: People won’t make a change...

HIV Therapeutic Vaccine Advances

Treatment Horizons Another Kind of Morning HIV therapeutic vaccines try to come of age by Mariel Selbovitz, MPJ, and David Miller Despite over three decades of research on...

Editing Genes for a Cure

Close to the Edit A functional cure candidate modifies genes to create HIV-resistant cells by Chael Needle Gary Blick, MD, AAHIVS, Medical & Research Director of CIRCLE...

Mighty Mouse

Mighty Mouse A humanized BLT mouse model creates a vital platform for drug discovery by Chael Needle In the early stages of drug discovery, many candidates that...

Host Restrictive Factors

The Deeper End of the Ocean Host restrictive factors create research excitement by Mariel Selbovitz, MPH, and David Miller The doors on viral host restrictive factors (HRFs),...

HPV Immunotherapy Research

Warts & All An immunotherapy candidate seeks to address complications from HPV by Chael Needle Human papillomavirus (HPV) is the most common sexually transmitted infection, but, according...

Introducing Dolutegravir

Treatment Horizons by Chael Needle Surpassing Expectations ViiV Healthcare introduces its first FDA-approved agent ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the...

AGS-004 Immunotherapy

Treatment Horizons by Chael Needle Fully Personalized An immunotherapy candidate stimulates T-cell responses via patient-specific antigens Previous studies have established immunotherapy candidate AGS-004, both as a single...

Safety Net

Treatment Horizons by Chael Needle A nonprofit creates a new support system for the uninsured Joining Merck and ViiV Healthcare, Gilead Sciences is now supporting and...